HYNR-CS-Allo ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症2

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03214146
(ClinicalTrials.gov)
February 1, 20179/7/2017Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALSAn Open-label, Phase 1 Trial for Safety and Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS)Amyotrophic Lateral SclerosisBiological: HYNRCS-Allo injHanyang University Seoul HospitalCorestem, Inc.Active, not recruiting25 Years80 YearsAll6Phase 1Korea, Republic of
2NCT01758510
(ClinicalTrials.gov)
December 201210/12/2012Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral SclerosisAn Open-label, Phase 1 Trial for Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS)Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Disease;Neurodegenerative Disease;Central Nervous System DiseaseGenetic: HYNR-CS-AlloHanyang University Seoul HospitalCorestem, Inc.Completed25 Years80 YearsAll6Phase 1Korea, Republic of